Inflammatory Intestinal Diseases最新文献

{"title":"Erratum.","authors":"","doi":"10.1159/iid/adeag008","DOIUrl":"https://doi.org/10.1159/iid/adeag008","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000550543.].</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"427-428"},"PeriodicalIF":0.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13653746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/iid/adeag007","DOIUrl":"https://doi.org/10.1159/iid/adeag007","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000551546.].</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"423-426"},"PeriodicalIF":0.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000553045","DOIUrl":"https://doi.org/10.1159/000553045","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000550543.].</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"313"},"PeriodicalIF":0.0,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13456668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Gastritis with Prominent IgG4-Positive Plasmacytosis Mimicking IgG4-Related Gastrointestinal Disease.","authors":"Kana Ayaki, Junko Fujisaki, Hiroshi Kawachi, Ryota Hokari","doi":"10.1159/000553074","DOIUrl":"10.1159/000553074","url":null,"abstract":"<p><strong>Introduction: </strong>IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by dense infiltration of IgG4-positive plasma cells across multiple organs, with well-established comprehensive diagnostic criteria and organ-specific criteria. However, diagnostic standards for IgG4-related disease involving the digestive tract remain relatively new and less clearly defined. We report a case suspicious for IgG4-related gastrointestinal disease (IgG4-GID). Although a definitive diagnosis could not be established, the clinical course of the patient and our assessment based on the most up-to-date evidence warrant attention.</p><p><strong>Case presentation: </strong>A 40-year-old man was referred to our hospital after esophagogastroduodenoscopy revealed irregular nodules in the gastric mucosa, raising the suspicion of scirrhous-type gastric cancer. He had no significant medical history and had undergone successful eradication of <i>Helicobacter pylori</i> infection 5 years previously. Endoscopic examination revealed a faded shallow depression, irregular nodules, and converging folds in the gastric body. Magnifying endoscopy with narrow band imaging demonstrated a tree-like appearance with several irregular vessels, raising the suspicion of mucosa-associated lymphoid tissue (MALT) lymphoma, and a biopsy was performed. Laboratory tests showed that serum gastrin, anti-gastric parietal cell antibody, and IgG4 levels were within normal ranges. Histopathological examination showed no evidence of MALT lymphoma but revealed bottom-heavy plasmacytosis, and IgG4 immunostaining demonstrated an IgG4/IgG-positive cell ratio exceeding 40%. Endoscopic ultrasound revealed mucosal and submucosal thickening, and computed tomography (CT) showed thickening of the gastric wall, while positron emission tomography-CT showed no abnormal uptake. During the 5-year follow-up, no significant changes were observed. Biopsy also revealed neutrophilic infiltration in the superficial layer. Although IgG4-related gastritis was suspected clinically, neutrophil infiltration is uncommon in IgG4-related gastritis, and further differential diagnosis is required.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic challenges of IgG4-rich gastric lesions and underscores the importance of distinguishing them from IgG4-GID and MALT lymphoma. When a definitive diagnosis cannot be established, careful long-term follow-up is warranted.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"374-381"},"PeriodicalIF":0.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Leucine-Rich Alpha-2 Glycoprotein Levels in Crohn's Disease Treatment.","authors":"Mizuki Komai, Shunichi Yanai, Makoto Eizuka, Tomofumi Oizumi, Yosuke Toya, Takayuki Matsumoto","doi":"10.1159/000553251","DOIUrl":"https://doi.org/10.1159/000553251","url":null,"abstract":"<p><strong>Introduction: </strong>Leucine-rich alpha-2 glycoprotein (LRG) is a novel serum biomarker that correlates with clinical activity of inflammatory bowel disease. It remains unclear whether LRG can predict treatment efficacy in Crohn's disease (CD). The aim of this study was to clarify the appropriate LRG cut-off value for predicting clinical remission of CD and whether pretreatment levels of LRG were associated with 52-week treatment persistence in patients treated with anti-tumor necrosis factor (anti-TNF) agents or ustekinumab.</p><p><strong>Methods: </strong>We retrospectively analyzed correlations between LRG and CRP levels and clinical activity (Crohn's disease activity index [CDAI]). The rates of drug persistence at 52 weeks from the start of treatment were compared between the ustekinumab group and the anti-TNF agent group.</p><p><strong>Results: </strong>The correlation between CDAI and LRG was statistically significant (<i>r</i> = 0.81, <i>p</i> < 0.01, respectively). The LRG cut-off value for predicting clinical remission was 15.3 µg/mL for the CDAI of <150 (AUC 0.90226, 95% CI: 0.815-0.989). There was a significant difference in drug continuance rate at 52 weeks between the anti-TNF agent group and ustekinumab group (100% [17/17] vs. 73.3% [11/15], respectively, <i>p</i> = 0.02). There was also a trend towards a lower LRG in the continuation group than in the discontinuation group in patients treated by ustekinumab.</p><p><strong>Conclusions: </strong>The LRG cut-off value for predicting clinical remission was 15.3 µg/mL for the CDAI of <150. Pretreatment levels of LRG may be a candidate marker for the prediction of efficacy in the use of ustekinumab.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"365-373"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Clinical and Biochemical Outcomes of IL-23p19 Inhibitors in Refractory Ulcerative Colitis: A Real-World Case Series.","authors":"Satohiro Matsumoto, Yurika Imai, Mina Morino, Takaya Miura, Haruka Otake, Takeshi Uehara, Hirosato Mashima","doi":"10.1159/000553498","DOIUrl":"https://doi.org/10.1159/000553498","url":null,"abstract":"<p><strong>Introduction: </strong>IL-23p19 inhibitors have emerged as therapeutic options for moderate-to-severe ulcerative colitis (UC), but real-world data describing their early clinical use remain limited.</p><p><strong>Methods: </strong>We conducted a single-center retrospective study of consecutive adults with moderate-to-severe UC who initiated mirikizumab (MIR) (<i>n</i> = 10), risankizumab (RIS) (<i>n</i> = 15), or guselkumab (GUS) (<i>n</i> = 15) between January 2024 and March 2026. Clinical Activity Index (CAI), clinical response, clinical remission, leucine-rich alpha-2 glycoprotein (LRG), and adverse events were assessed over 12 weeks.</p><p><strong>Results: </strong>The cohort was predominantly treatment-refractory, with prior exposure to biologics or Janus kinase inhibitors in 67-100% of patients. Median CAI decreased from 5.5 to 3.5 with MIR, from 8 to 3 with RIS, and from 7 to 3 with GUS by week 12. Week 12 clinical remission rates were 40%, 67%, and 67%, respectively. Median LRG levels decreased from 15.9 to 14.5 μg/mL, from 13.2 to 10.0 μg/mL, and from 14.4 to 11.1 μg/mL, respectively. Three patients discontinued therapy because of primary non-response: two treated with MIR and one treated with RIS. No serious adverse events occurred.</p><p><strong>Conclusion: </strong>This 40-patient real-world cohort suggests short-term clinical and biochemical improvement after initiation of IL-23p19 inhibitors in refractory UC, with no serious adverse events observed during the 12-week observation period. These findings should be interpreted as preliminary and hypothesis-generating, and larger prospective studies are warranted to clarify long-term outcomes.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"337-344"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infliximab-Associated IgA Vasculitis Masquerading as Crohn's Disease Relapse: Leukocytoclastic Vasculitis Confirmed on Duodenal Biopsy - A Case Report.","authors":"Tomoe Kazama, Shinji Yoshii, Kotaro Akita, Sae Ohwada, Yoshihiro Yokoyama, Keisuke Ishigami, Shintaro Sugita, Reiko Watanabe, Hisashi Uhara, Hiroshi Nakase","doi":"10.1159/000553413","DOIUrl":"https://doi.org/10.1159/000553413","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor necrosis factor (TNF)-α inhibitors are widely used in the management of inflammatory bowel disease (IBD), yet they can rarely provoke paradoxical immune-mediated complications such as vasculitis.</p><p><strong>Case presentation: </strong>We describe the case of a 38-year-old man with ileocolonic Crohn's disease (CD) in remission during infliximab (IFX) maintenance therapy who presented with fever and diarrhea, raising the initial concerns of disease relapse. He subsequently developed severe abdominal pain, melena, and palpable purpura on his lower legs. Laboratory tests revealed elevated serum IgA and D-dimer levels, proteinuria, and microscopic hematuria. Video capsule endoscopy and colonoscopy revealed no active inflammatory lesions in the small or large bowels. However, an upper gastrointestinal (GI) endoscopy revealed multiple sharply circumscribed circular ulcers in the second portion of the duodenum. Histological assessment of biopsy specimens from the skin lesions and the duodenal ulcer base confirmed leukocytoclastic vasculitis. Based on the purpura and renal and GI involvement, IFX-associated IgA vasculitis was diagnosed. Withdrawal of IFX followed by oral prednisolone therapy and transition to ustekinumab led to rapid clinical recovery.</p><p><strong>Conclusion: </strong>This case highlights IgA vasculitis as a critical diagnostic consideration in patients with IBD receiving anti-TNF-α therapy who present with acute abdominal symptoms, especially when GI involvement precedes the appearance of purpura (\"herald enteritis\"). Biopsy of the duodenal ulcer base may provide decisive clues for differentiating vasculitis from CD relapse, thereby preventing inappropriate intensification of CD treatment.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"353-358"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice Patterns in Inflammatory Bowel Disease in Pakistan: A National Survey of Physician Confidence and Therapeutic Strategies.","authors":"Talia Azad, Junaid Mushtaq, Ghias Un-Nabi Tayyab, Om Parkash, Maliha Aziz, Tauseef Ali, Muhammad Umair, Ali Syed Gillani, Muslim Atiq","doi":"10.1159/000553104","DOIUrl":"https://doi.org/10.1159/000553104","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence and prevalence of inflammatory bowel disease (IBD) are increasing in South Asia, including Pakistan. Biologic therapies have transformed IBD management; however, physician confidence in initiating these therapies and real-world prescribing patterns remain variable.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among physicians involved in IBD care across Pakistan using an online questionnaire. A total of 100 physicians were invited to participate; 99 respondents with complete data were included in the analysis. The survey assessed demographics, training background, practice setting, therapeutic preferences, physician-reported confidence in initiating biologic therapy, and perceived barriers. Descriptive statistics and comparative analyses were performed.</p><p><strong>Results: </strong>Most respondents were male (83.8%), with the largest age group being 35-44 years (43.4%). Most participants had completed formal gastroenterology training (87.9%), with 17.2% reporting overseas training. Overseas training was significantly associated with greater confidence in initiating biologic therapy for UC induction (<i>p</i> = 0.013) and CD induction (<i>p</i> = 0.010). Confidence with therapy strongly corresponded with early advanced therapeutic strategies, including upfront anti-TNF and oral targeted therapy use in both UC and CD (all <i>p</i> < 0.05). Male physicians were more comfortable with CD maintenance therapy (<i>p</i> = 0.036).</p><p><strong>Conclusion: </strong>Physician confidence in initiating biologic therapy for IBD in Pakistan is associated with training exposure and therapeutic approach. Addressing barriers such as infection screening, cost, and access, along with strengthening IBD-focused training programs, may support more consistent and guideline-concordant care.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"345-352"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Ustekinumab on Skin Reactions Induced by Tumor Necrosis Factor-Alpha Inhibitors in Patients with Inflammatory Bowel Disease.","authors":"Koji Fujimoto, Shuhei Hosomi, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara","doi":"10.1159/000552245","DOIUrl":"10.1159/000552245","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor necrosis factor-alpha (TNF-α) inhibitors sometimes induce skin reactions in patients with Crohn's disease (CD) and ulcerative colitis (UC). Ustekinumab (UST) has been reported to be effective in treating TNF-α inhibitor-induced skin reactions. Here, we aimed to investigate the efficacy of UST on skin reactions and its long-term efficacy in the treatment of CD and UC.</p><p><strong>Methods: </strong>CD and UC patients who switched to UST due to skin reactions (skin reaction group) or secondary failure of TNF-α inhibitors (non-skin reaction group) in our hospital between June 2017 and September 2023 were included. The primary outcome was the efficacy of UST for skin reactions, classified as complete remission, partial remission, or no response. The secondary outcome was cumulative UST continuation, assessed using Kaplan-Meier analysis and Cox proportional hazards models. Inverse probability of treatment weighting (IPTW) was performed after adjusting for age, clinical remission status, and type of inflammatory bowel disease (CD or UC).</p><p><strong>Results: </strong>Eighty-two patients (CD, 68; UC, 14) were included; 20 developed skin reactions, most commonly psoriasiform dermatitis (30%). After switching to UST, 15 patients achieved complete remission of the skin reaction, and four achieved partial remission. After IPTW adjustment, the UST continuation rate did not differ significantly between groups (<i>p</i> = 0.205), and skin reactions were not associated with UST continuation (hazard ratio 0.55; 95% CI: 0.24-1.26; <i>p</i> = 0.159).</p><p><strong>Conclusions: </strong>UST was effective for 95% of TNF-α inhibitor-induced skin reactions without affecting long-term UST continuation, supporting its clinical utility.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"260-269"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn's Disease.","authors":"Shinya Yoshida, Atsushi Nishida, Yoshihiro Yokota, Takayuki Imai, Masashi Ohno, Takuji Iwashita","doi":"10.1159/000553291","DOIUrl":"10.1159/000553291","url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic control of inflammation is a key treatment goal in Crohn's disease. However, real-world endoscopic outcomes of risankizumab assessed by paired balloon-assisted enteroscopy (BAE) remain limited. We examined endoscopic outcomes at the visit closest to week 52 after risankizumab initiation using paired BAE.</p><p><strong>Methods: </strong>We retrospectively studied adults with Crohn's disease who initiated risankizumab. The primary analysis set comprised 42 patients who underwent BAE at baseline and at the visit closest to week 52. Endoscopic activity was quantified using the Simple Endoscopic Score for Crohn's Disease (SES-CD). Endoscopic remission was defined as SES-CD ≤4 with a decrease of ≥2 points from baseline, and mucosal healing was defined as SES-CD ≤2.</p><p><strong>Results: </strong>In the paired BAE cohort (<i>n</i> = 42), the median SES-CD improved from 9 at baseline to 2 at follow-up (<i>p</i> < 0.0001). At follow-up, 76.2% (32/42) achieved endoscopic remission and 52.4% (22/42) achieved mucosal healing. Endoscopic remission was more frequent in bio-naïve than bio-experienced patients (93.3% vs. 66.7%, <i>p</i> = 0.054), whereas mucosal healing rates were similar (53.3% vs. 51.9%, <i>p</i> = 0.92).</p><p><strong>Conclusion: </strong>In this real-world Japanese cohort, risankizumab was associated with significant endoscopic improvement assessed by paired BAE at follow-up. Endoscopic remission and mucosal healing rates were high in the paired BAE cohort, particularly for endoscopic remission among bio-naïve patients.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"325-336"},"PeriodicalIF":0.0,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13456675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}